top of page
S379_CD45RO FOXP3 40x_2Snapshot1.tif

Don't stop there!

Icone collegamenti_Tavola disegno 1 copia 45.png

​Check out our press releases and keep up to date.

Lever Bio In-Licenses a Linoleic Acid-based Treatment as a Novel Potentiator for T Cell Therapy from the University of Turin to Advance it towards Preclinical and Clinical Development

  • Immagine del redattore: Lever Bio
    Lever Bio
  • 9 lug
  • Tempo di lettura: 2 min

Turin, 9th July 2025 – Lever Bio, a biotech company pioneering immuno-oncology innovation, announces an in-licensing agreement with the University of Turin to accelerate the development of  LVB-006, a novel linoleic acid (LA)-based approach for T cell therapy. This agreement grants  Lever Bio exclusive rights to advance and commercialize LVB-006, leveraging the expertise of  Professor Teresa Manzo, Professor of Pathology at the University of Turin and distinguished  researcher in tumor metabolism and immune cell reprogramming, to explore the therapeutic  potential of LA-driven metabolic modulation in enhancing T cell-based cancer therapies. 


While T-cell therapies, such as CAR-T, have revolutionized cancer treatment, their application in  solid tumors remains severely limited due to manufacturing complexities, high costs, and  challenges in sustaining T cell persistence. Studies indicate that a large proportion of patients with  solid tumors — up to 90% — are unable to benefit from current T cell therapies due to these  limitations. LVB-006 aims to address this critical gap by enhancing T cell metabolic fitness,  improving their survival and functionality in the tumor microenvironment. 


Professor Manzo has dedicated her career to understanding how lipid metabolism influences  immune responses in cancer. Her research has revealed the critical role of polyunsaturated fatty  acids in shaping T cell functionality, paving the way for innovative strategies to improve T cell  persistence, expansion, and anti-tumor activity with possible immediate applications in clinical  practice.  


“Partnering with Professor Manzo and the University of Turin is an exciting step forward in our  mission to develop cutting-edge immuno-oncology solutions,” said Chiara Donini, Project Manager  at Lever Bio. “Her groundbreaking work in tumor metabolism aligns perfectly with our vision to  leverage metabolic reprogramming as a powerful tool to enhance T cell immunotherapies. We look  forward to unlocking the full potential of LVB-006 and its interplay with existing and upcoming  cell therapies.” 


“We are pleased to see our research translated into a potential therapeutic solution through this  agreement with Lever Bio,” said Teresa Manzo, Principal Investigator and Assistant Professor at  University of Turin. “Our approach to use lipids to achieve metabolic and functional  reprogramming in T cell therapy has great potential to overcome key limitations of current  immunotherapies, and we look forward to seeing how LVB-006 will develop further in the coming  years.” 


This in-licensing agreement reinforces Lever Bio’s commitment to next-generation immuno metabolic therapies, combining tumor biology, metabolism, and cell therapy to push the boundaries  of cancer treatment innovation.


Contacts:


Lever Bio

Lever Bio is a biotechnology company focused on developing next-generation immuno-oncology therapies. By leveraging metabolic and immune system reprogramming, the company aims to overcome resistance to existing cancer treatments, particularly in solid tumors. Through strategic in-licensing agreements and collaborations with leading research institutions, Lever Bio is dedicated to advancing novel biologics to improve patient outcomes.


About the University of Turin – Molecular Biotechnology Center (MBC) 

The Molecular Biotechnology Center (MBC) at the University of Turin is a hub of excellence in  biomedical research, specializing in molecular medicine, oncology, and regenerative medicine.  MBC scientists work on cutting-edge projects to understand disease mechanisms and develop  innovative therapeutic approaches, often collaborating with biotech companies and healthcare  institutions.

bottom of page